Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium

Version 1 : Received: 4 September 2021 / Approved: 7 September 2021 / Online: 7 September 2021 (16:26:51 CEST)

How to cite: Scott, G.D.; Arnold, M.R.; Beach, T.G.; Gibbons, C.H.; Kanthasamy, A.G.; Lebovitz, R.M.; Lemstra, A.W.; Shaw, L.M.; Teunissen, C.E.; Zetterberg, H.; Taylor, A.S.; Graham, T.C.; Boeve, B.F.; Gomperts, S.N.; Graff-Radford, N.R.; Moussa, C.E.; Poston, K.L.; Rosenthal, L.S.; Sabbagh, M.N.; Walsh, R.R.; Weber, M.T.; Armstrong, M.J.; Bang, J.A.; Bozoki, A.C.; Domoto-Reilly, K.; Duda, J.E.; Fleisher, J.E.; Galasko, D.R.; Galvin, J.E.; Goldman, J.G.; Holden, S.K.; Honig, L.S.; Huddleston, D.E.; Leverenz, J.B.; Litvan, I.; Manning, C.A.; Marder, K.S.; Pantelyat, A.Y.; Pelak, V.S.; Scharre, D.W.; Sha, S.J.; Shill, H.A.; Zoltan, M.; Quinn, J.F.; Irwin, D.J. Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Preprints 2021, 2021090133 (doi: 10.20944/preprints202109.0133.v1). Scott, G.D.; Arnold, M.R.; Beach, T.G.; Gibbons, C.H.; Kanthasamy, A.G.; Lebovitz, R.M.; Lemstra, A.W.; Shaw, L.M.; Teunissen, C.E.; Zetterberg, H.; Taylor, A.S.; Graham, T.C.; Boeve, B.F.; Gomperts, S.N.; Graff-Radford, N.R.; Moussa, C.E.; Poston, K.L.; Rosenthal, L.S.; Sabbagh, M.N.; Walsh, R.R.; Weber, M.T.; Armstrong, M.J.; Bang, J.A.; Bozoki, A.C.; Domoto-Reilly, K.; Duda, J.E.; Fleisher, J.E.; Galasko, D.R.; Galvin, J.E.; Goldman, J.G.; Holden, S.K.; Honig, L.S.; Huddleston, D.E.; Leverenz, J.B.; Litvan, I.; Manning, C.A.; Marder, K.S.; Pantelyat, A.Y.; Pelak, V.S.; Scharre, D.W.; Sha, S.J.; Shill, H.A.; Zoltan, M.; Quinn, J.F.; Irwin, D.J. Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Preprints 2021, 2021090133 (doi: 10.20944/preprints202109.0133.v1).

Abstract

The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy Body Dementia (LBD), which includes Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD). The meeting featured eight internationally known scientists from Europe and the United States and attracted over 200 scientists and physicians from academic centers, the National Institutes of Health and the pharmaceutical industry. Methods for confirming and quantifying the presence of Lewy body and Alzheimer pathology as well as novel biomarkers were discussed.

Keywords

cerebrospinal fluid; alpha-synuclein; skin biopsy; seeded aggregation assays; tau, amyloid; Lewy body dementia

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.